Loading stock data…
YDES
$4.80-0.26 (-5.05%)
Market ClosedLast close May 1
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.80
Potential Upside
5%
Whystock Fair Value$5.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Tai...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$375.17M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.22
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.74%
Volume
Today's trading volume
3,986
Recent News
Breeze Holdings Acquisition (YDES) Rises 31% Over the Past Month
In recent events, YD Bio Limited's addition to the NASDAQ Composite Index has elevated the company's market standing, while Breeze Holdings Acquisition (YDES) has seen a 31% price rise over the past month. This surge coincides with significant developments, including a business combination with Taiwan-based YD Biopharma, signaling a move to strengthen their presence in the biopharmaceutical industry. These corporate actions place the company's recent performance against the backdrop of a...
Top Midday Gainers
Professional Diversity Network (IPDN) said Friday it signed a non-binding memorandum of understandin